T2 Biosystems (NASDAQ:TTOO) Stock, Quote.Headers.trade-ideas

T2 Biosystems

T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

AIRE

AMBC

AUDC

FGEN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSDT

NUVO

PLTN

PLTR

TCBP

TRUP

TTOO

ZETA

Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Intraday Update

ABEO

AZTR

CALX

CDTX

CHCI

CSLR

CTCX

FCEL

GWAV

HIBB

HRTX

HSTM

JAGX

JBLU

KULR

LICN

MESO

MLEC

MSCI

OPRT

PALI

PEGY

PHIO

RNAC

ROKU

SMFL

SMXT

SPCB

SPCE

SPOT

TIRX

TRSG

YYGH

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Hibbett - logo

AGBA

CDNS

CHNR

IBRX

NUWE

TOVX

Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

T2 Biosystems Inc

T2 Biosystems Receives FDA Clearance To Market T2Candida Panel For Pediatric Patients, The Only Test Detecting Sepsis-Causing Candida Species Directly From Blood In 3-5 Hours Without Blood Culture; Panel Detects Five Candida Species Responsible For 95% Of U.S. Bloodstream Infections

<ul>
<li>Finalizing a 510(k) premarket notification application for the T2Resistance&#xAE; Panel planned to be filed with the U.S. Food and Drug Administration (FDA) during the fourth quarter of 2024.</li>
<li>The previously submitted 510(k) premarket notification to expand use of the T2Candida&#xAE; Panel to detect pediatric Candida infections is pending clearance with the FDA.</li>
<li>Advanced internal validation and plans to submit a 510(k) premarket notification to the FDA to expand the use of its FDA-cleared T2Bacteria&#xAE; Panel to detect pediatric bacterial infections.</li>
<li>The Company maintains its plan to launch the T2Lyme&#x2122; Panel as a Laboratory Developed Test (LDT); however, it now plans to build or buy its own laboratory rather than launch through a partnership.
<ul>
<li>Pursuing non-dilutive funding to complete the development, validation, and clinical studies for a diagnostic test to detect Candida auris, following the completion of feasibility and early development in collaboration with the U.S. Centers for Disease Control and Prevention (CDC).</li>
</ul>
</li>
</ul>

T2 Biosystems Provides Updates On New Product Development Pipeline Progress

<a href="https://www.tga.gov.au/resources/artg/459987" title="https://www.tga.gov.au/resources/artg/459987">https://www.tga.gov.au/resources/artg/459987</a>

Biotech

Global

General

T2 Biosystems  Gets Australian Approval For Its T2Candida In Vitro Diagnostic For The Detection Of Sepsis-Causing Fungal Pathogens From Whole Blood

T2 Biosystems shares are trading higher after the company reported better-than-expected Q2 EPS results. Also, Canaccord Genuity maintained a Hold rating on the stock and raised its price target from $3 to $5.

Canaccord Genuity analyst Kyle Mikson maintains T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) with a Hold and raises the price target from $3 to $5.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on T2 Biosystems, Raises Price Target to $5

Guidance

T2 Biosystems Continues To Expect FY24 Total Sepsis Product Revenue Of $10M - $11M, Representing Growth Of 49% To 64% Y/Y

T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.97) by 31.96 percent. The company reported quarterly sales of $1.952 million which missed the analyst consensus estimate of $2.100 million by 7.05 percent. This is a 0.61 percent decrease over sales of $1.964 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

T2 Biosystems Q2 2024 GAAP EPS $(0.66) Beats $(0.97) Estimate, Sales $1.952M Miss $2.100M Estimate

Marks Continued International Expansion Following Recent Hong Kong And Macau Entry; Aims To Improve Sepsis Care Globally, Says CEO John Sperzel

T2 Biosystems Announces Exclusive Distribution Agreement In Malaysia And Indonesia; To Sell T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, And T2Resistance Panel

T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau. Under the terms of the agreement, T2 Biosystems will sell the T2Dx&#xAE; Instrument, the T2Bacteria&#xAE; Panel, the T2Candida&#xAE; Panel, and the T2Resistance&#xAE; Panel through the newly appointed distributor.

T2 Biosystems Announces Commercial Expansion Through Hong Kong And Macau Distributor; T2 Biosystems Will Sell The T2dD Instrument, The T2Bacteria Panel, The T2Candida Panel, And The T2Resistance Panel Through The Newly Appointed Distributor

T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities ("MVLS") requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.

T2 Biosystems Regains Compliance With Nasdaq

<h3>Gainers</h3>
<ul>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares moved upwards by 31.66% to $0.17. The company's market cap stands at $20.6 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock increased by 23.56% to $2.22. The market value of their outstanding shares is at $26.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares moved upwards by 23.35% to $0.1. The company's market cap stands at $3.4 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock moved upwards by 23.29% to $0.14. The market value of their outstanding shares is at $3.0 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock increased by 19.98% to $3.88. The market value of their outstanding shares is at $40.9 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 24.1% to $0.81 during Thursday's regular session. The market value of their outstanding shares is at $41.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 22.17% to $1.51. The company's market cap stands at $1.3 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock decreased by 20.99% to $3.29. The market value of their outstanding shares is at $190.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares fell 17.31% to $8.6. The market value of their outstanding shares is at $87.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Biotricity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCY#NASDAQ">BTCY</a>) stock decreased by 11.41% to $1.01. The company's market cap stands at $9.5 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) stock decreased by 10.22% to $5.36. The market value of their outstanding shares is at $72.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BTCY

ELTX

EYEN

LSDI

NNVC

NRXP

OMER

ONCO

SCPX

SINT

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

T2 Biosystems shares are trading higher after the company announced an $8 million private placement.

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares moved upwards by 22.8% to $12.87. The market value of their outstanding shares is at $234.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 20.57% to $1.0. The market value of their outstanding shares is at $50.7 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 67.0% to $0.76 during Wednesday's regular session. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 50.35% to $0.42. The company's market cap stands at $1.1 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock decreased by 37.84% to $3.27. The company's market cap stands at $2.1 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares declined by 33.12% to $0.88. The company's market cap stands at $33.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.91% to $0.73. The market value of their outstanding shares is at $54.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares declined by 18.27% to $1.61. The market value of their outstanding shares is at $3.6 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BBLG

BOLT

NTRB

OPRX

TCON

VRPX

YTEN

12 Health Care Stocks Moving In Wednesday's Intraday Session

Health Care

Financing

Offerings

T2 Biosystems Announced $8M Private Placement Including The Purchase And Sale Of An Aggregate Of 2.02M Shares, Series A Warrants To Purchase Up To 2.02M Shares, And Short-term Series B Warrants To Purchase Up To 2.02M At $3.95/Share

T2 Biosystems Announces LOI For Partnership On Lyme Disease

Shares of Zeta Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NASDAQ">ZETA</a>) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and increased its <a href="https://www.benzinga.com/quote/ZETA/earnings">second-quarter revenue guidance</a>.
Zeta Global posted GAAP loss of 23 cents per share, compared to market expectations for a loss of 25 cents per share. The company's quarterly sales came in at $194.947 million topping estimates of $187.112 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Zeta Global shares jumped 15.3% to $15.00 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>reAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) gained 65.8% to $1.42 in pre-market trading after the company announced the completion of its previously announced acquisition of Naamche.</li>
<li>FibroGen, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) gained 27.5% to $1.48 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) rose 26.8% to $1.84 in today's pre-market trading. TC BioPharm recently the execution of a non-binding letter of intent to acquire a company pursuing the development of innovative CAR-T thera.</li>
<li>Ambac Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBC#NYSE">AMBC</a>) shares rose 19.1% to $18.00 in pre-market trading following better-than-expected first-quarter earnings.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares gained 16.4% to $13.57 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Fundamental Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGF#NASDAQ">FGF</a>) jumped 15.3% to $1.51 in pre-market trading after the company announced the acquisition of Strong/MDI Screen Systems by FG Acquisition Corp. at a $30 million valuation.</li>
<li>T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares gained 11.3% to $4.04 in pre-market trading after the company reported mixed first-quarter financial results and announced the execution of a territory exclusive distribution agreement in Qatar.</li>
<li>Symbotic Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NYSE">SYM</a>) shares rose 11.7% to $46.85 in pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) shares gained 7.6% to $29.70 in pre-market trading after the company posted better-than-expected results for its first quarter.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) fell 34% to $0.0953 in pre-market trading after the company filed for offering of up to 432.5 million shares by selling stockholders.</li>
<li>GreenPower Motor Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) shares declined 28.6% to $1.30 in pre-market trading after the company reported pricing of $2.3 million underwritten public offering.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) shares fell 20.2% to $0.9575 in pre-market trading after dipping 10% on Monday.</li>
<li>Strong Global Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGE#NYSE">SGE</a>) fell 15.1% to $2.25 pre-market trading. Fundamental Global announced acquisition of Strong/MDI Screen Systems, Inc. by FG Acquisition Corp. at a $30 million valuation.</li>
<li>Holdco Nuvo Group D.G Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) fell 13.7% to $4.53 in pre-market trading after jumping 157% on Monday.</li>
<li>Plutonian Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTN#NASDAQ">PLTN</a>) shares fell 12.8% to $8.32 in pre-market trading after surging 57% on Monday.</li>
<li>Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) shares declined 13% to $20.68 in pre-market trading following first-quarter results.</li>
<li>AudioCodes Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) shares fell 11.3% to $10.10 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Helius Medical Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares declined 9.9% to $2.18 in pre-market trading after the company announced pricing of $6.4 million public offering.</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) fell 9.3% to $22.85 pre-market trading following soft revenue guidance.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38661451/disney-electronic-arts-and-3-stocks-to-watch-heading-into-tuesday">Disney, Electronic Arts And 3 Stocks To Watch Heading Into Tuesday</a>

T2 Biosystems shares are trading higher after the company reported mixed Q1 financial results and announced the execution of a territory exclusive distribution agreement in Qatar.

Reiterated 2024 Financial Outlook The Company continues to expect full year 2024 total sepsis product revenue of $10.0 million to $11.0 million, representing growth of 49% to 64%, compared to $6.7 million in 2023. The Company's 2024 revenue guidance consists entirely of sepsis product revenue and does not include potential sales of the T2Biothreat Panel or the T2Lyme Panel.

T2 Biosystems Reiterates Guidance

T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) reported quarterly losses of $(2.66) per share which missed the analyst consensus estimate of $(2.27) by 17.18 percent. This is a 97.98 percent increase over losses of $(132.00) per share from the same period last year. The company reported quarterly sales of $2.061 million which beat the analyst consensus estimate of $2.000 million by 3.05 percent. This is a 0.82 percent decrease over sales of $2.078 million the same period last year.

T2 Biosystems Q1 2024 GAAP EPS $(2.66) Misses $(2.27) Estimate, Sales $2.061M Beat $2.000M Estimate

T2 Biosystems files for $150M mixed securities shelf

T2 Biosystems Q2 2024 Earnings Preview

Notable earnings after Monday's close

T2 Biosystems GAAP EPS of -$0.66 beats by $0.31, revenue of $1.95M misses by $0.15M

T2 Biosystems announces commercial expansion through Malaysia and Indonesia distributor

T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
T2 Biosystems (NASDAQ:<a href="https://investorplace.com/stock-quotes/ttoo-stock-quote/">TTOO</a>) just reported results for the second quarter of 2024.<ul><li>T2 Biosystems reported earnings per share of -66 cents. This was above the analyst estimate for EPS of -97 cents.</li><li>The company reported revenue of $1.95 million.</li><li>This was 7.05% worse than the analyst estimate for revenue of $2.10 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/ttoo-stock-earnings-t2-biosystems-for-q2-of-2024/">TTOO Stock Earnings: T2 Biosystems Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TTOO Stock Earnings: T2 Biosystems Beats EPS, Misses Revenue for Q2 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!



Moving stocks this morning are earnings reports, clinical trial results and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Imunon (NASDAQ:<a href="https://investorplace.com/stock-quotes/imnn-stock-quote/">IMNN</a>) stock is rocketing more than 133% alongside <a href="https://finance.yahoo.com/news/imunon-report-topline-results-phase-200500840.html">Phase 2 clinical trial results</a>.</li>



<li>Jet AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/">JTAI</a>) shares are soaring over 57% despite a lack of news this morning.</li>



<li>Enveric Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/envb-stock-quote/">ENVB</a>) stock is surging more than 32% with strong early morning trading.</li>



<li>Inspirato (NASDAQ:<a href="https://investorplace.com/stock-quotes/ispo-stock-quote/">ISPO</a>) shares are rising close to 26% without any clear news this morning.</li>



<li>Pharming (NASDAQ:<a href="https://investorplace.com/stock-quotes/phar-stock-quote/">PHAR</a>) stock is heading over 21% higher ahead of its <a href="https://www.nasdaq.com/press-release/pharming-group-report-second-quarter-and-first-half-2024-financial-results-august-1-0">upcoming earnings report</a>.</li>



<li>Sprouts Farmers Market (NASDAQ:<a href="https://investorplace.com/stock-quotes/sfm-stock-quote/">SFM</a>) shares are increasing more than 17% after <a href="https://investorplace.com/earning-results/2024/07/sfm-stock-earnings-sprouts-farmers-market-for-q2-of-2024/?utm_source=barchart&amp;utm_medium=allother">releasing its Q2 earnings</a>.</li>



<li>Harmonic (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlit-stock-quote/">HLIT</a>) stock is climbing over 17% with its <a href="https://www.nasdaq.com/press-release/harmonic-announces-second-quarter-2024-results-2024-07-29">Q2 earnings report</a>.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) shares are gaining more than 15% on Tuesday morning.</li>



<li>T2 Biosystems (NASDAQ:<a href="https://investorplace.com/stock-quotes/ttoo-stock-quote/">TTOO</a>) stock is getting an over 14% boost with its <a href="https://www.nasdaq.com/press-release/t2-biosystems-announces-second-quarter-2024-financial-results-2024-07-29">latest earnings report</a>.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) shares are up more than 14% after announcing <a href="https://www.nasdaq.com/press-release/investor-one-one-meeting-requests-open-29th-annual-enercom-denver-energy-investment">investor meeting plans</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>QXO (NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) stock is crashing over 80% after <a href="https://finance.yahoo.com/news/high-flying-qxo-erases-36-221350996.html">announcing a private placement</a>.</li>



<li>BIMI (NASDAQ:<a href="https://investorplace.com/stock-quotes/bimi-stock-quote/">BIMI</a>) shares are plummeting more than 23% on Tuesday morning.</li>



<li>Ekso Bionics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ekso-stock-quote/">EKSO</a>) stock is diving over 22% alongside its <a href="https://finance.yahoo.com/news/ekso-bionics-ekso-reports-q2-214505963.html">Q2 earnings results</a>.</li>



<li>Symbotic (NASDAQ:<a href="https://investorplace.com/stock-quotes/sym-stock-quote/">SYM</a>) shares are tumbling more than 18% after <a href="https://finance.yahoo.com/news/symbotic-inc-sym-reports-q3-213008077.html">reporting a Q3 loss</a>.</li>



<li>Lattice Semiconductor (NASDAQ:<a href="https://investorplace.com/stock-quotes/lscc-stock-quote/">LSCC</a>) stock is taking an almost 18% beating with its <a href="https://seekingalpha.com/article/4707817-lattice-semiconductor-corporation-lscc-q2-2024-earnings-call-transcript?source=feed_all_articles">latest earnings report</a>.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are falling over 17% <a href="https://investorplace.com/2024/07/why-is-lipella-pharmaceuticals-lipo-stock-up-149-today/">after a rally yesterday</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is dropping more than 16% as it continues downward movement <a href="https://investorplace.com/2024/07/why-is-cognition-therapeutics-cgtx-stock-down-33-today/">on study results</a>.</li>



<li>NLS Pharmaceutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nlsp-stock-quote/">NLSP</a>) shares are sliding over 14% <a href="https://investorplace.com/2024/07/why-is-nls-pharmaceutics-nlsp-stock-up-48-today/">following a merger rally yesterday</a>.</li>



<li>Troops (NASDAQ:<a href="https://investorplace.com/stock-quotes/troo-stock-quote/">TROO</a>) stock is decreasing more than 13% today.</li>



<li>Loop Media (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) shares close out our pre-market stock movers down over 12% after <a href="https://www.stocktitan.net/news/LPTV/loop-media-inc-announces-new-partnership-and-nationwide-launch-of-u3mffuxudp5v.html">jumping yesterday on a new partnership</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-30th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

T2 Biosystems ( ($TTOO) ) just unveiled an update. T2 Biosystems, Inc. is on the brink of launching several innovative direct-from-blood diagnostic...

T2 Biosystems: Pioneering Rapid Diagnostic Tests Launch

The latest announcement is out from T2 Biosystems ( ($TTOO) ). T2 Biosystems has announced FDA clearance for its T2Candida Panel for use in pediatr...

T2 Biosystems Gains FDA Nod for Pediatric Sepsis Test

AMKR

BIMI

BYON

CGTX

CORT

DTCK

EKSO

ENVB

FFIV

HLIT

HOLX

HSII

IMNN

ISPO

JTAI

KFRC

LIPO

LPTV

LSCC

NLSP

NTST

PHAR

PLOW

PRTS

RMBS

SAFE

SANM

SBAC

SERV

TLRY

TROO

VRNS

WELL

Press Releases

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor

Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024

Contracts

T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor

T2 Biosystems Announces Second Quarter 2024 Financial Results

T2 Biosystems to Attend Upcoming Investor Conferences

T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

T2 Biosystems Provides Updates on its New Product Development Pipeline Progress

T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

T2 Biosystems

T2 Biosystems (TTOO) Forecast

T2 Biosystems (NASDAQ:TTOO) Stock, Quote.Headers.trade-ideas